biosynthesis and contains vicinal RGD motif that bind specifically to aVb3 and aVb5 integrins. Since chondrostatin reaches the highest level during cartilage formation and it inhibits angiogenesis, it is an excellent candidate for the molecular mechanism by which cartilage remains avascular. 
Purpose: There is increasing evidence for intra-articular hyaluronic acid and especially corticosteroids in the treatment of osteoarthritis (OA) from studies using fluroscopy guidance or triple ultrasound guided injections. Having previously demonstrated the accuracy of ultrasound guided injection and how competency can be achieved we aimed to demonstrate the duration of objective improvement in pain, function and global health assessment in patients with moderate/severe hip OA with a single intraarticular injection. Methods: 77 patients with hip OA were recruited to a prospective, randomised controlled trial and randomised to one of four groups: standard care (non-injection group), normal saline (3 mls), non-animal stabilized hyaluronic acid (durolane, 3 mls/60 mg) and methylprednisolone acetate (depomedrone, 3 mls/120 mg). All patients met the ACR criteria for hip OA. Those in the injection groups received a single ultrasound guided injection. All baseline data were obtained with both patients and investigators blinded to the group allocation, and injection patients remained blinded throughout the study. The primary outcome measure was 'worst pain' using a numerical rating scale (NRS 0−10), and other outcome measures included the aggregate pain and function scales of the WOMAC. These evaluations were performed at baseline and weeks 1, 4, 8 and 16. Results: Mean age was 69 (SD 8) years. Mean BMI was 28.5 (SD 5.2) kg×m −2 . The 4 groups were matched with respect to age, BMI, and scores of the outcome measures (ANOVA). At week 1 and week 4 there was a significant improvement in NRS pain, as well as WOMAC pain and function for the steroid arm with the differences being statistically significant compared to all the other groups; the effect sizes were striking: 1.5 for NRS pain, 1.9 for WOMAC pain and 1.3 for WOMAC function at week 1. There were 22 responders as defined by the OMERACT-OARSI responder criteria in an intention to treat analysis at week 1: 14 in the steroid group (74%), 4 in saline group (21%), 2 in durolane group (11%) and 2 in non-injection group (10%); Chi-squared test for comparison between the groups, p < 0.001. At 8 weeks the differences were still significant between the steroid group and the saline group (NRS pain: t test, p 0.018). Conclusions: This is the first single ultrasound guided injection study in hip OA comparing a moderately high dose of corticosteroid, hyaluronic acid, a control injection and standard care. Our data demonstrate the efficacy of intra-articular corticosteroid, with a statistically significant and clinically important improvement in pain and function sustained for at least 8 weeks post injection, suggesting this is an important and practical treatment option for those with moderate/severe hip OA. Purpose: Purpose: Our previous studies had shown that bilateral total meniscectomy (BTM) in merino sheep resulted in pathological changes in articular cartilage (AC), subchondral bone and synovial tissues that were progressive and simulated the development of early human osteoarthritis (OA). We previously used this animal model to evaluate potential diseasemodifying OA drugs. Mesenchymal stem cells (MSC) + bio-scaffolds have been widely investigated for their ability to enhance repair of chondral/osteochondral defects, but their chondroprotective effects when injected directly into OA joints has received limited attention. The objective of this study was to address this deficiency using immunoselected Stro-3+ mesenchymal precursor stem cells (MPC) in the BTM model. 
A12 DOSE DEPENDENT CHONDROPROTECTIVE EFFECTS OF ALLOGENIC STRO-3+ MESENCHYMAL PRECURSOR STEM CELLS FOLLOWING DIRECT INTRA-ARTICULAR INJECTION INTO JOINTS OF AN OVINE MODEL OF EARLY OSTEOARTHRITIS

